Neuphoria Therapeutics (NEUP) investor relations material

Executive summary

• Clinical-stage CNS drug developer paused all R&D after BNC210 failed a Phase 3 trial for social anxiety disorder; PTSD program also paused pending strategic review.

• Strategic alternatives, including mergers or acquisitions, are being actively pursued with financial advisors engaged.

• CEO transitioned to interim consulting role; nearly all employees terminated and facilities closed as part of restructuring.

Financial highlights

• Net loss of $0.5 million for the quarter ended March 31, 2026, compared to net income of $11.3 million in the prior year quarter.

• Revenue dropped to $0 from $15 million year-over-year due to absence of milestone payments.

• Cash and cash equivalents were $19.4 million as of March 31, 2026.

• Accumulated deficit reached $186.9 million.

• Cash used in operations was $13.6 million for the nine months ended March 31, 2026.

Outlook and guidance

• Current cash expected to fund operations beyond Q4 fiscal 2027, assuming continued cost curtailment.

• No assurance of future profitability; further capital may be needed if development resumes.

• Strategic review may result in merger, acquisition, or other transaction; timeline and outcome uncertain.